Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with...
4 insider purchases on record · latest filing 2026-09-11.
Insiders have also filed 26 sale transactions at MGX.